In short: Cagrilintide is a long-acting, acylated analogue of the hormone amylin and an unapproved investigational compound, supplied by Vexar Lab strictly for in-vitro laboratory research and not approved for human consumption. It is a current reference compound in amylin-receptor and metabolic research. Before ordering any peptide, research buyers should confirm purity of at least 99% by HPLC, identity confirmation by mass spectrometry, and clear batch numbering with a corresponding certificate of analysis (COA).
What is Cagrilintide?
Cagrilintide is a synthetic, long-acting amylin analogue developed by Novo Nordisk as a once-weekly, acylated peptide. It is described in the literature as a non-selective amylin-receptor agonist acting at calcitonin and amylin receptor complexes. It remains an investigational, proprietary compound: as of 2026 it is not approved by the FDA or EMA, and much of its development has focused on the combination with semaglutide known as CagriSema, which is also not approved. Researchers use cagrilintide as a tool to study long-acting amylin-receptor pharmacology.
What does the research investigate?
Published research, including Phase 2 and Phase 3 clinical programmes, has investigated cagrilintide’s effects on amylin-receptor signalling, food intake, body weight, and glycaemic control, both as a monotherapy and in combination with GLP-1 receptor agonists. Trials have also examined its role in bone metabolism. As an unapproved investigational drug, all reported effects are research findings only and do not establish safety or efficacy for any general human use; the compound is not authorised for therapeutic use in any market. Always read the primary sources directly.
Purity and quality: what research buyers should check
- Purity of at least 99% by HPLC — confirm the figure against the batch-specific COA rather than a generic specification sheet.
- Identity confirmation by mass spectrometry — the measured mass should match the expected molecular weight of the peptide.
- Batch numbering — every vial should trace back to a documented production batch and its analytical records.
Vexar Lab supplies Cagrilintide as a pack of 10 vials, ≥99% HPLC-verified, batch-numbered, with mass-spec confirmation.
Handling and storage
Cagrilintide is supplied lyophilised. Standard laboratory practice for lyophilised peptides applies: store the sealed vials cold and protected from light, reconstitute only with an appropriate sterile solvent immediately before use, and aliquot to avoid repeated freeze-thaw cycles. Reconstituted peptide is generally less stable than the dry powder and should be kept refrigerated and used within a short working window. Follow your own institution’s handling protocols.
Wholesale supply
Vexar Lab supplies Cagrilintide to research buyers and resellers in packs of 10 vials, with a £300 minimum order, bulk pricing on volume, £45 flat worldwide shipping, and optional custom labelling for resellers.
Frequently asked questions
Is Cagrilintide approved for human use?
No. Cagrilintide is an unapproved investigational compound, supplied by Vexar Lab strictly as a research material for in-vitro laboratory use. It is not sold for human consumption, and nothing here constitutes medical or dosing guidance.
What purity does Vexar Lab guarantee?
Each batch is verified at ≥99% by HPLC with identity confirmed by mass spectrometry, and every vial is batch-numbered against its COA.
How is it shipped and packaged?
It ships lyophilised in packs of 10 vials, with £45 flat worldwide shipping and batch documentation available on request.
This guide is provided for research-only purposes. Cagrilintide is an unapproved investigational compound supplied strictly for in-vitro laboratory research and is not approved for human consumption. No medical, therapeutic, or dosing advice is given or implied.
Related: GLP-1 research peptides · Lab standards & purity testing · Shop all research peptides · How to buy research peptides wholesale